Anaesthesia and orphan disease: a patient with spinal muscular atrophy type III (Wohlfart-Kugelberg-Welander syndrome) undergoing laparoscopic cholecystectomy

Autor: Aarnout J. Pijl, A. Karim El Harchaoui, Boudewijn J. Dwars, Marcel Soesan

Publikováno v: European journal of anaesthesiology, 32(3), 211-213. Wolters Kluwer Health

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e48d45a2828cd447fd830f6f0ea9209e
https://pure.amc.nl/en/publications/anaesthesia-and-orphan-disease-a-patient-with-spinal-muscular-atrophy-type-iii-wohlfartkugelbergwelander-syndrome-undergoing-laparoscopic-cholecystectomy(796fe1c8-2080-4050-a2cc-2ea16ac5f406).html

Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study

Autor: Tom Teerlink, Roger K. Schindhelm, Peter G. Scheffer, Geesje M Dallinga-Thie, Jan Albert Kuivenhoven, Piet J. Kostense, Robert J. Heine, Karim El-Harchaoui, Michaela Diamant, Marjan Alssema, Jacqueline M. Dekker, Giel Nijpels

Publikováno v: Metabolism: clinical and experimental, 59(6), 854-860. W.B. Saunders Ltd
Alssema, M J, El-Harchaoui, K, Schindhelm, R K, Diamant, M, Nijpels, G, Kostense, P J, Teerlink, T, Heine, R J, Dallinga-Thie, G M, Kuivenhoven, J A, Dekker, J M & Scheffer, P G 2010, ' Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study ', Metabolism, Clinical and Experimental, vol. 59, no. 6, pp. 854-860 . https://doi.org/10.1016/j.metabol.2009.10.002
Metabolism, Clinical and Experimental, 59(6), 854-860. W.B. Saunders Ltd

The aim of the study was to test whether fasting or postprandial cholesteryl ester transfer protein (CETP) concentrations are associated with postprandial changes in high-density lipoprotein cholesterol (HDL-c) concentrations after fat-rich or carboh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e684d045a8c516df03bd17e98b4188e3
https://pubmed.ncbi.nlm.nih.gov/20005542

Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins

Autor: John J. P. Kastelein, Karim El Harchaoui, Fatima Akdim, Mieke D. Trip, Erik S.G. Stroes

Publikováno v: American journal of cardiovascular drugs : drugs, devices, and other interventions. 8(4)

Low-density lipoprotein-cholesterol (LDL-C) lowering is the mainstay of the current treatment guidelines in the management of cardiovascular risk. HMG-CoA reductase inhibitors (statins) are currently the most effective LDL-C-lowering drugs. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6fd1a764bcf52a04d3c02fa7645c28b
https://pubmed.ncbi.nlm.nih.gov/18690757

Antisense apolipoprotein B-100 as novel treatment for hypercholesterolemia: focus on ISIS 301012

Autor: John J.P. Kastelein, Karim El Harchaoui, Erik S.G. Stroes, Fatima Akdim

Publikováno v: FUTURE LIPIDOLOGY, 2(4), 387-393. Taylor and Francis Ltd.

Antisense oligonucleotides (ASOs) are single-stranded DNA-like molecules, which can effectively limit the availability of specific mRNA, resulting in less translation of the encoded protein. Since these antisense drugs largely distribute to hepatic c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e54f7b3314c193faa5f1d42951a3beb4
https://doi.org/10.2217/17460875.2.4.387

Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia

Autor: Erik S.G. Stroes, Johannes H. M. Levels, Karim El Harchaoui, Sotirios Tsimikas, Jan Albert Kuivenhoven, John J.P. Kastelein, Kewei Pu, Aeilko E. Zwinderman, Radjesh J. Bisoendial, G. Kees Hovingh

Publikováno v: Arteriosclerosis, thrombosis, and vascular biology, 25(9), E133-E134. Lippincott Williams and Wilkins

To the Editor: A large proportion of clinical events cannot be prevented during statin therapy, which calls for novel drug targets to further improve cardiovascular outcome. In particular, HDL-increasing strategies hold great promise. The impact of d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::967a506c0b85dc1273b19511c2c40789
https://pure.amc.nl/en/publications/consequences-of-cholesteryl-ester-transfer-protein-inhibition-in-patients-with-familial-hypoalphalipoproteinemia(884676ba-3ba6-458b-83da-f6a240755c6d).html